LAB
Standard BioTools, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.62
+0.85%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 84.4M | 85.3M | 174.4M | 106.3M | 97.9M |
| Cost of Revenue | 41.5M | 42.8M | 90.2M | 55.9M | 60.9M |
| Gross Profit | 42.9M | 42.5M | 84.3M | 50.5M | 37.1M |
| Operating Expenses | |||||
| R&D Expense | 14.0M | 26.0M | 62.4M | 25.9M | 37.4M |
| SG&A Expense | 76.2M | 109.9M | 156.6M | 87.5M | 102.3M |
| General & Admin Expense | 16.4M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 20.7M | — | 40.5M | 13.6M | 13.6M |
| Total Operating Expenses | 110.8M | 135.8M | 259.5M | 127.0M | 153.3M |
| Cost and Expenses | 152.4M | 178.6M | 349.7M | 182.9M | 214.2M |
| Operating Income (EBIT) | (76.5M) | (93.3M) | (175.2M) | (76.6M) | (116.2M) |
| Non-Operating | |||||
| Interest Income | 5.2M | 9.2M | 20.2M | 5.6M | 2.2M |
| Interest Expense | 5.0K | 26.0K | 3.3M | 4.6M | 4.3M |
| Net Interest Income | 5.2M | 9.2M | 16.9M | 1.0M | (2.1M) |
| Other Non-Op Income/Expense | 3.5M | (3.4M) | 36.9M | 2.4M | (76.7M) |
| Non-Operating Income (excl Interest) | 9.3M | 3.4M | (40.2M) | (7.0M) | 72.4M |
| EBT (Pre-Tax Income) | (73.0M) | (96.7M) | (138.3M) | (74.2M) | (192.9M) |
| Income Tax Expense | (35.9M) | (37.9M) | 573.0K | 452.0K | (2.8M) |
| Bottom Line | |||||
| Net Income | (39.2M) | (74.9M) | (138.9M) | (74.7M) | (190.1M) |
| Earnings from Cont. Ops | (8.8M) | (58.8M) | (138.9M) | (74.7M) | (190.1M) |
| Earnings from Discont. Ops | (30.4M) | (16.1M) | — | — | — |
| Bottom Line Net Income | (39.2M) | (74.9M) | (184.9M) | (74.7M) | (190.1M) |
| Per Share | |||||
| Basic EPS | ($0.11) | ($0.20) | ($0.52) | ($0.94) | ($2.43) |
| Diluted EPS | ($0.11) | ($0.20) | ($0.52) | ($0.94) | ($2.43) |
| Revenue Per Share | $0.22 | $0.22 | $0.49 | $1.34 | $1.25 |
| Shares | |||||
| Basic Shares Outstanding | 390.9M | 381.6M | 352.7M | 79.2M | 78.3M |
| Diluted Shares Outstanding | 390.9M | 381.6M | 352.7M | 79.2M | 78.3M |
| Profitability Metrics | |||||
| EBITDA | (81.8M) | (85.7M) | (118.1M) | (54.5M) | (173.6M) |
| D&A | 4.0M | 11.0M | 16.9M | 15.2M | 15.0M |
| EBIT | (66.0M) | (96.7M) | (135.0M) | (69.6M) | (188.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026